



## **“A Practical Update on Treatment Options and Clinical Outcomes with Biologicals in Asthma and CRSwNP”**

16-17 November 2021

### **PROGRAM & SPEAKERS**

**Webinar Day 1: Tuesday 16th November 2021 (9:00am-11.30 am CET).  
Repeated recorded with live moderation (5:00pm - 7:30 pm CET)**

---

**Chairs & Moderation: Prof. Zuzana Diamant**

#### **Welcome by the Chair**

Prof. Zuzana Diamant, (Netherlands)

#### **Type-2 Inflammation: a key trait in asthma**

Dr. Ian Pavord, (UK) – 15 Minutes

#### **Update on CRSwNP care for not-ENT's**

Prof. Peter Hellings, (Belgium) – 15 Minutes

#### **Biologics in Asthma and CRSwNP: updates on clinical outcomes from recent studies**

Prof. Nicola Hanania, (USA) – 15 Minutes

#### **Biologics for uncontrolled Severe Asthma (+/- Comorbidities): which for whom and when?**

Prof. Leif Bjermer, (Sweden) – 15 Minutes

#### **Biologics for Children with uncontrolled Severe Asthma: which for whom and when?**

Prof. Milos Jesenak, (Slovenia) – 15 Minutes

#### **“I can see clearly now” Realistic expectations on Effectiveness from existing Biologics**

Prof. Nicola Hanania, (USA) – 15 Minutes

#### **Discussion and Announcement of Day Two**

Prof Zuzana Diamant, (The Netherlands)

**Webinar Day 2: Wednesday 17th November 2021 (9:00am-11.30 am CET).  
Repeated recorded with live moderation (5:00pm - 7:30 pm CET)**

---

**Chair & Moderation: Prof. Zuzana Diamant**

#### **Guideline-based management of patients with uncontrolled Severe Asthma with Comorbidities**

Prof. Zuzana Diamant, (The Netherlands) – 15 Minutes



(continued)

**Webinar Day 2: Wednesday 17th November 2021 (9:00am-11.30 am CET).  
Repeated recorded with live moderation (5:00pm - 7:30 pm CET)**

## **PATIENT PRESENTATIONS**

### **Type-2 Inflammation as a treatment target in severe asthma**

Prof. Ian Pavord, (UK) – 15 Minutes

### **Patient with Severe Uncontrolled Allergic Asthma (anti-IgE treatment including switching)**

Prof. Nicola Hanania, (USA) – 15 Minutes

### **Patient(s) with Uncontrolled (moderate-severe) Asthma with CRSwNP (anti-IL4/13 treatment vs anti-IL5 treatment)**

Prof. Leif Bjermer, (Sweden) – 15 Minutes

### **Pediatric patient(s) with Severe Uncontrolled Asthma (anti-IgE/IL5/IL4-13 treatment)**

Prof. Milos Jesenak, (Slovakia) – 15 Minutes

### **Discussion and Close**

Prof. Zuzana Dimant, (Netherlands)